

Oncology Today with Dr Neil Love: Novel Agents Under Investigation in Multiple Myeloma (Presentation Video)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What is the target of the various chimeric antigen receptor (CAR) T-cell platforms under evaluation for patients with multiple myeloma (MM)?
 - a. CD19
 - b. B-cell maturation antigen (BCMA)
 - c. CD20
2. Which of the following drug types best describes the mechanism of action of the novel agent melflufen?
 - a. Antibody-drug conjugate
 - b. Cereblon E3 ligase modulator ("CELMoD")
 - c. Peptide-drug conjugate
3. What was observed with regard to the activity and adverse-event profile of the recently FDA-approved anti-BCMA antibody-drug conjugate belantamab mafodotin in the Phase II DREAMM-2 study for patients with heavily pretreated MM?
 - a. Unacceptably high rates of Grade 5 adverse events
 - b. A low overall response rate (<20%)
 - c. Frequent ocular toxicities
4. Which of the following drug types best describes the mechanism of action of the novel agents iberdomide and CC-92480?
 - a. Anti-CD38 antibody
 - b. Bcl-2-targeted agent
 - c. BCMA-targeted agent
 - d. CELMoD
5. In the Phase III BELLINI trial, which demonstrated a significant improvement in progression-free survival with the addition of venetoclax to bortezomib/dexamethasone for patients with relapsed/refractory MM both in the overall study population and in the subset of patients with t(11;14) mutations, what was observed in terms of overall survival with the addition of venetoclax?
 - a. Significant improvement in the overall study population but not in the subset of patients with t(11;14) mutations
 - b. Significant improvement for patients with t(11;14) mutations
 - c. Significant improvement for patients without t(11;14) mutations